scPharmaceuticals Inc. (SCPH) is all set to resubmit its New Drug Application for Furoscix by April 15, 2022. Furoscix is being developed for the treatment of congestion due to fluid overload in adult patients with worsening New York Heart Association (NYHA) Class II and Class III heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization.
from RTT - Earnings https://ift.tt/CcnJlZT
via IFTTT
No comments:
Post a Comment